Nevolat (Liraglutide)

Liraglutide binds to the GLP‑1 receptor on pancreatic beta cells, enhancing insulin secretion only when glucose levels are elevated. It simultaneously suppresses glucagon release, slows gastric emptying, and acts on brain centres that regulate appetite, leading to lower post‑prandial glucose excursions and reduced caloric intake.

The dosing regimen for Nevolat is individualized by the prescribing healthcare professional. Typically, treatment starts with a low dose that is gradually increased based on therapeutic response and tolerability, but the exact amount and titration schedule must be determined by the prescriber.

Safety of liraglutide during pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Nevolat, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Nevolat (liraglutide) shares the core mechanism of GLP‑1 receptor activation with other agents in its class, but it differs in dosing frequency, molecular size and specific trial data. For example, some GLP‑1 agonists are weekly injections, whereas liraglutide is administered daily, offering more flexible titration but requiring more frequent administration.

Nevolat must be stored at 2‑8 °C (refrigerated) in its original carton, protected from light. Do not freeze or shake the vial. If the product has been kept at room temperature for more than a few hours, it should be discarded according to the supplier’s stability guidelines.

Nevolat is supplied as a sterile solution for subcutaneous injection. It is typically injected into the abdomen, thigh or upper arm using a pre‑filled pen or syringe, following the injection technique taught by a healthcare professional. The injection site should be rotated to minimise local reactions.

Serious adverse events associated with liraglutide include pancreatitis, gallbladder disease, severe hypoglycaemia (especially when combined with insulin or sulfonylureas), and rare thyroid C‑cell tumours observed in animal studies. Patients should be instructed to seek immediate medical attention if they experience persistent abdominal pain, vomiting, or signs of an allergic reaction.

Nevolat is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and in patients with known hypersensitivity to liraglutide or any excipients. Caution is also advised for those with severe renal impairment, active pancreatitis, or uncontrolled thyroid disease.